Maltofer, syrup 10mg/ml, 150ml

Composition

Active ingredient:

iron in the form of a polymaltose complex of iron (III) hydroxide 10 mg;

Auxiliary substances:

methylparahydroxybenzoate;

propylparahydroxybenzoate;

sodium hydroxide;

sorbitol solution 70%;

ethanol 96% (3.25 mg);

water;

sucrose;

cream flavor;

Pharmacological action

Maltofer contains iron in the form of a polymaltose complex of iron (III) hydroxide.

This macromolecular complex is stable and does not release iron in the form of free ions in the gastrointestinal tract. The structure of Maltofer® is similar to the natural iron compound ferritin.

Due to this similarity, iron (III) enters the bloodstream from the gut by active transport. Absorbed iron binds to ferritin and is stored in the body, mainly in the liver.

Then, in the bone marrow, it is included in the composition of hemoglobin.

Iron, which is part of the polymaltose complex of iron (III) hydroxide, does not have pro-oxidant properties, unlike simple iron salts.

There is a correlation between the severity of iron deficiency and the level of its absorption (the greater the severity of iron deficiency, the better the absorption).

The most active absorption process occurs in the duodenum and small intestine.

Maltofer®preparation does not cause staining of tooth enamel.

Indications

Latent iron deficiency and clinically expressed iron deficiency (iron deficiency anemia);

prevention of iron deficiency in women during pregnancy, breastfeeding, during the childbearing period, in children, including in adolescence, in adults (for example, vegetarians and the elderly).

Use during pregnancy and lactation

In controlled studies in pregnant women after the first trimester of pregnancy, there was no undesirable effect of the drug on the mother and fetus.

There are no data on the undesirable effect of the drug on the fetus in the first trimester of pregnancy.

Contraindications

• iron overload (for example, hemosiderosis and hemochromatosis);
• violation of iron utilization (lead anemia, sideroachrestic anemia);
• non-iron-deficient anemia (hemolytic or megaloblastic, caused by a lack of vitamin B12).

Side effects

From the digestive tract:  sensation of fullness, epigastric pressure, nausea, constipation or diarrhea; possible dark staining of the stool due to the release of unabsorbed iron, which is not clinically significant.

Interaction

Interaction with other drugs was not detected.

How to take, course of use and dosage

Inside.

Take with or immediately after a meal. The daily dose of the drug depends on the degree of iron deficiency.

The duration of treatment for clinically expressed iron deficiency (iron deficiency anemia) is 3-5 months, until the hemoglobin level normalizes.

After that, the drug should be continued in the dosage for the treatment of latent iron deficiency for several more months, and for pregnant women, at least until delivery to restore iron reserves.

The duration of treatment for latent iron deficiency is 1-2 months.

In the case of clinically expressed iron deficiency, normalization of hemoglobin levels and replenishment of iron reserves occurs only 2-3 months after the start of treatment.

Overdose

To date, no intoxication or signs of iron overload have been reported in cases of overdose of the drug.

Special instructions

When prescribing the drug to patients with diabetes mellitus, it should be borne in mind that 1 ml of drops for oral use contains 0.01 XE,1 ml of syrup – 0.04 XE,1 chewable tablet – 0.04 XE.

Maltofer® does not cause staining of tooth enamel.

Form of production

syrup

Storage conditions

In a dark place, at a temperature not exceeding 25 °C

Shelf life

3 years

Active ingredient

Iron III hydroxide polymaltose

Conditions of release from pharmacies

By prescription

Dosage form

solution for oral use

Description

Children as prescribed by a doctor, Pregnant women as prescribed by a doctor, Adults as prescribed by a doctor, Nursing mothers as prescribed by a doctor

Indications

Bleeding, Anemia, Iron Deficiency Prevention